Market capitalization | $623.10m |
Enterprise Value | $376.33m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.63 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-109.70m |
Free cash flow (TTM) Free cash flow | $-86.99m |
Cash position | $248.98m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
9 Analysts have issued a Olema Pharmaceuticals Inc forecast:
9 Analysts have issued a Olema Pharmaceuticals Inc forecast:
Dec '23 | |
Current assets | 267 267 |
Fixed assets | 10 10 |
Total assets | 277 277 |
Dec '23 | |
Equity | 254 254 |
Debt capital | 23 23 |
Total capital | 277 277 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Sean Bohen |
Employees | 74 |
Founded | 2006 |
Website | www.olema.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.